The Karen Leung Foundation is encouraged to see continued progress in the global fight against HPV-related diseases. A newly announced Phase 2 clinical trial by Amplexd Therapeutics is investigating an innovative EGCG-based therapy, a compound derived from green tea, as a potential non-invasive treatment option for HPV infections.

Amplexd Therapeutics, Inc. (“Amplexd”), a U.S.-based clinical-stage biotechnology company focused on women’s health and underserved therapeutic areas, today announced authorization from the Hong Kong Department of Health to initiate a Phase 2 clinical trial evaluating its novel EGCg-based investigational therapy for precancerous cervical lesions associated with high-risk human papillomavirus (hr-HPV).

This development reflects growing momentum in advancing accessible and effective solutions for HPV management, which remains a critical area in cervical cancer prevention. As research evolves, such breakthroughs offer renewed hope for expanding treatment pathways and improving outcomes for women worldwide.

We will continue to follow advancements in this space and advocate for increased awareness, early detection, and innovative care solutions in the fight against cervical cancer.

Read more about Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy: https://www.globenewswire.com/news-release/2026/05/19/3297462/0/en/amplexd-therapeutics-initiates-phase-2-clinical-trial-of-investigational-egcg-based-hpv-therapy.html